Natera (NTRA: NASDAQ) Investor Relations Material

Overview

Diagnostic company Natera, Inc. has developed and globally commercialized molecular testing services, according to a company statement. Among its offerings: Panorama, a prenatal test for chromosomal abnormalities in fetuses, including those in twin pregnancies; Horizon, carrier screening for genetic variations; Vistara, single-gene NIPT screening for 25 disorders, including skeletal, cardiac, and neurological conditions; Spectrum, a preimplantation genetic test for couples undergoing IVF; and non-invasive prenatal paternity testing, which allows couples to establish paternity prior to birth. The company has also developed Signatera, a ctDNA blood test for disease recurrence in patients previously diagnosed with cancer; Altera, a tissue-based genomic profiling test; Prospera, a test that assesses active rejection in kidney transplants; and Renasight, a kidney gene panel test. Natera offers products through its direct sales force as well as through distribution partners and laboratory partners, one of which is BGI Genomics, with whom Natera has a partnership agreement to develop, manufacture, and commercialize NGS-based genetic testing assays. The company also has an arrangement with Foundation Medicine to develop personalized, circulating tumor DNA monitoring assays. Natera was established in Austin, Texas, in 2003.